- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Silver47 Exploration
Purpose Bitcoin ETF
Jindalee Lithium
Black Swan Graphene
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
NuLife Sciences will begin a preclinical trial on the “NuLife Technique.”
NuLife Sciences (OTCQB:NULF) will begin a preclinical trial on the “NuLife Technique.”
As quoted in the press release:
The NuLife Technique, a means to potentially eliminate the need for organ or tissue matching between donor and recipient in organ transplants and the necessity for anti-rejection drugs after surgery.
The trial, commenced on August 8th at Florida International University, and will evaluate the NuLife process in an autologous setting, meaning an organ is removed from and transplanted back to the same donor. The objective of the study is to prove that the NuLife Technique is viable.
This first of a series of pre-clinical trials, a kidney will be removed from a pig, the NuLife Technique will be applied to the kidney, and it will be transplanted back into the original “donor” pig. Two weeks after the transplant, both kidneys (the control kidney left in the animal and the kidney that had the NuLife Process applied) will be histologically compared. Results from the trial will be published as a series, with findings presented as each step of the pre-clinical work is completed.
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.